# A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.

> **NCT05878522** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 43 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** sisunatovir
- **DRUG:** placebo
- **DRUG:** moxifloxacin
- **DRUG:** sisunatovir

## Key facts

- **NCT ID:** NCT05878522
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-15
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05878522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05878522, "A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05878522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*